Clin Gastroenterol Hepatol. 2017 Jul;15(7):1124-1126. doi: 10.1016/j.cgh.2017.03.004. Epub 2017 Mar 11.
Thrift AP, Vaughan TL, Anderson LA, Whiteman DC, El-Serag HB.
Barrett’s esophagus (BE) is a premalignant lesion for esophageal adenocarcinoma, a rapidly increasing, highly fatal cancer.1 Clinical guidelines recommend screening for BE in those with chronic gastroesophageal reflux disease (GERD) and at least 2 risk factors (eg, >50 years of age, white race, obese, tobacco smoking history).2,3 However, providing clinicians with a tool that allows them to estimate a patients’ risk may better aid them in deciding who to screen for BE and make future resource utilization more efficient. The Michigan Barrett’s Esophagus pREdiction Tool (M-BERET) predicts risk for BE in men attending primary care using information on their frequency of GERD symptoms, age, waist-to-hip ratio (WHR), and pack-years of cigarette smoking.4 In internal validation, the M-BERET discriminated reasonably well between men with and without BE, with an area under the receiver-operating characteristic curve (AUROC) of 0.72. This was significantly better than using GERD symptoms alone (0.72 vs 0.61; P < .001).4 However, this prediction tool needs to be validated in an independent population before its use can be recommended in clinical practice.